Special Issue

Clinical Genetics and Genomics of Neurodegenerative Diseases

Message from the Guest Editors

This Special Issue, entitled "Clinical Genetics and Genomics of Neurodegenerative Diseases", is intended to provide a platform for a wide range of reviews, research articles, communications, and technical notes related to the genomics of neurodegenerative disorders. We encourage manuscripts to have a strong genomic component that may include, but is not limited to, machine learning of high-throughput data associated with Alzheimer's disease and other dementias, genome-wide association studies, proteomic studies, functional studies for Alzheimer's disease-related genes or variants or other neurodegenerative diseases, personalized genetics, gene expression analyses, clinical trials with a genetic component, rare variant analyses, and other bioinformatics analyses of Alzheimer's disease using DNA or RNA sequencing data. We are especially interested in how genetics can influence therapeutic responses and better inform clinical practice, whether through earlier diagnoses and screening or patient-centered treatment plans. Please contact the with questions related to the scope of this Special Issue.

Guest Editors

Dr. Justin Miller

1. Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY 40536 USA
2. Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY 40536, USA
3. Division of Biomedical Informatics, Department of Internal Medicine, University of Kentucky, Lexington, KY 40536, USA
4. Department of Microbiology, Immunology, and Molecular Genetics, University of Kentucky, Lexington, KY 40536 USA

Dr. Laura Ibanez

1. Department of Psychiatry, Washington University in Saint Louis School of Medicine, 4444 Forest Park, Campus Box 8134, Saint Louis, MO 63110, USA
2. NeuroGenomics and Informatics Center, Washington University in Saint Louis School of Medicine, Saint Louis, MO 63110, USA
3. Department of Neurology, Washington University in Saint Louis School of Medicine, Saint Louis, MO 63110, USA

Deadline for manuscript submissions

31 July 2026

MDPI

Biomedicines

**an Open Access Journal
by MDPI**

**Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed**

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).